This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, J C Articles by Bottorff, D Search for Related Content PubMed PubMed Citation Articles by Stone, J C Articles by Bottorff, D

 Previous Article  |  Next Article 

Mol Cell Biol. 1993 December; 13(12): 7311-7320

Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction.

Department of Biochemistry, University of Alberta, Edmonton, Canada.

ABSTRACT

The GTPase activity of p21ras is stimulated by GTPase-activating proteins (GAPs) such as p120GAP and the product of the neurofibromatosis 1 gene, which may negatively regulate p21 function. GAPs are also proposed effectors of ras. We have sought activating substitutions in c-H-ras in the region encoding the effector domain, on the rationale that such mutations would dissociate effector function from negative regulation by GAP. One such activating mutation, Pro-34-->Arg, encodes protein that is substantially bound to GTP in vivo. In vitro, this protein is not stimulated by GAPs, and its binding to p120GAP is grossly impaired. The results support the idea that the p21 structural requirements for effector function and GAP interaction are quite different and suggest that some molecule(s) other than p120GAP serves as the ras effector. In contrast to the results obtained with p120GAP, the Pro-34-->Arg p21 species is effectively coupled to the raf-1 product, as judged from electrophoretic mobility shifts of the Raf-1 phosphoprotein.

This article has been cited by other articles:

• Schubbert, S., Bollag, G., Lyubynska, N., Nguyen, H., Kratz, C. P., Zenker, M., Niemeyer, C. M., Molven, A., Shannon, K. (2007). Biochemical and Functional Characterization of Germ Line KRAS Mutations. Mol. Cell. Biol. 27: 7765-7770 [Abstract] [Full Text]  
• Zenker, M., Lehmann, K., Schulz, A. L., Barth, H., Hansmann, D., Koenig, R., Korinthenberg, R., Kreiss-Nachtsheim, M., Meinecke, P., Morlot, S., Mundlos, S., Quante, A. S, Raskin, S., Schnabel, D., Wehner, L.-E., Kratz, C. P, Horn, D., Kutsche, K. (2007). Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J. Med. Genet. 44: 131-135 [Abstract] [Full Text]  
• Wiesner, S. M., Jones, J. M., Hasz, D. E., Largaespada, D. A. (2005). Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood 106: 1054-1062 [Abstract] [Full Text]  
• Zong, H., Raman, N., Mickelson-Young, L. A., Atkinson, S. J., Quilliam, L. A. (1999). Loop 6 of RhoA Confers Specificity for Effector Binding, Stress Fiber Formation, and Cellular Transformation. J. Biol. Chem. 274: 4551-4560 [Abstract] [Full Text]  
• Ebinu, J. O., Bottorff, D. A., Chan, E. Y., Stang, S. L., Dunn, R. J., Stone, J. C. (1998). RasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs. Science 280: 1082-1086 [Abstract] [Full Text]  
• Winkler, D. G., Johnson, J. C., Cooper, J. A., Vojtek, A. B. (1997). Identification and Characterization of Mutations in Ha-Ras That Selectively Decrease Binding to cRaf-1. J. Biol. Chem. 272: 24402-24409 [Abstract] [Full Text]